Investing.com -- Shares of Indivior, a company known for its anti-opioid treatments, rose as much as 6.3% to 738.5p.

This surge came after the company reported its Q1 total net revenue of $266 million, surpassing the consensus estimate of $243 million, as per the analysis by Jefferies.

In addition to the strong revenue report, Indivior also reiterated its financial guidance for the fiscal year 2025.

The company remains confident in its financial outlook, which is a positive signal to investors and the market.

Furthermore, the company expressed optimism about the performance of its key product, SUBLOCADE. Indivior anticipates that SUBLOCADE will see growth in the second half of the year.

This expectation further boosted investor confidence and contributed to the rise in the company’s share price.

Indivior’s recent performance and positive outlook for its key product suggest a promising future for the company, reflected in the stock market’s positive response.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.